Rentosertib shifts multiple proteomic aging clocks toward younger age profiles in IPF trial
Researchers applied six proteomic aging clocks to serum samples from a phase 2a trial of rentosertib in people with idiopathic pulmonary fibrosis and found treatment-associated shifts toward younger predicted biological-age…